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ABSTRACT 
Pediatric cancer survivors are a steadily growing population; however chronic 
anthracycline-induced cardiotoxicity (AIC) is a serious long-term complication 
leading to substantial morbidity. We aimed to identify new genes and low-
frequency variants influencing the susceptibility to AIC for pediatric cancer 
patients. We studied the association of variants on the Illumina HumanExome 
BeadChip array in 93 anthracycline-treated pediatric cancer patients. In addition 
to single-variant association tests we carried out a gene-based analysis to 
investigate the joint effects of common and low-frequency variants on chronic 
AIC. Although no single-variant showed an association with chronic AIC which 
was statistically significant after correction for multiple testing, we identified a 
novel significant association for GPR35 (G protein-coupled receptor 35) by 
gene-based testing, a gene with potential roles in cardiac physiology and 
pathology (P=4.0x10-6, PFDR=0.02). The greatest contribution to this observed 
association was made by rs12468485, a missense variant (p.Thr253Met, 
c.758C>T, minor allele frequency=0.04), the T allele being associated with 
increased risk of chronic AIC and more severe symptomatic cardiac 
manifestations at low anthracycline doses. This study reveals GPR35 as a 
novel susceptibility gene associated with chronic AIC in pediatric cancer 
patients and the results emphasize the need for very large studies to reveal 
additional susceptibility variants. 
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INTRODUCTION  
Anthracycline chemotherapeutic agents are highly effective and widely used to 
treat childhood cancers1, but their clinical use is compromised by cardiotoxicity, 
especially for late-onset disease2,3. Children typically develop chronic dilated 
cardiomyopathy, which can progress with time to congestive heart failure and 
eventual demise (up to 7.3% of patients after 30-years)3,4, although survivors 
treated with anthracyclines can be asymptomatic for several years (up to 57% 
of patients)5.  
Several studies6-21 have identified genetic variants associated with 
anthracycline-induced cardiotoxicity (AIC). Most have been hypothesis-driven 
candidate-gene studies and have focused on common genetic variants (minor 
allele frequency (MAF) ≥5%). Still, a substantial portion of genetic susceptibility 
to AIC remains unexplained. There is increasing evidence that low-frequency 
variants (MAF<5%) also play an important role in the genetic architecture of 
complex traits22, but the role of this type of variation in AIC has not been 
explored thus far.  
We performed a genome-wide association analysis of 93 anthracycline-treated 
pediatric cancer patients using the Illumina HumanExome Beadchip, which is 
enriched for low-frequency coding variants (>80% variants with MAF ≤1%)23. 
Due to the low power to detect individual low-frequency AIC susceptibility 
alleles we explored the joint associations of variants using gene-based tests. 
We also performed gene-enrichment and pathway analyses. 
MATERIALS AND METHODS 
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Patients 
283 anthracycline-treated pediatric cancer patients at the La Paz University 
Hospital and the Niño Jesús University Hospital in Madrid and at the University 
Clinic of Navarra in Pamplona were reviewed between 2010 and 2014 and 
relevant clinical information was abstracted from medical records 
(Supplementary Table 4). All patients were treated with doxorubicin, 
daunorubicin or epirubicin as part of their chemotherapy protocol.  
AIC was defined as early-onset (occurring within 1 year after anthracycline 
treatment completion) or late-onset (occurring >1 year after anthracycline 
therapy completion) chronic left ventricle (LV) dysfunction assessed by 
echocardiogram measurements and evidenced by shortening fraction (SF) or 
symptoms/signs of severe mitral valve insufficiency, pericardial effusion, left 
ventricular hypertrophy or pulmonary hypertension. The criteria for determining 
a symptomatic event were established by pediatric cardiologists. To avoid inter-
observer and intra-observer variability in echocardiographic evaluations and to 
better differentiate between cases and controls, we defined as cases patients 
with SF≤27% at any time after anthracycline treatment completion. Controls 
were patients who had no symptoms or signs of cardiac complications and had 
normal echocardiograms (SF≥35%) during and after therapy. To rule out acute 
AIC, only echocardiograms obtained 30 days or more after an anthracycline 
dose were considered. All pediatric cancer patients had normal cardiac function 
before commencing anthracycline therapy. 93 out of 283 (33%) patients fulfilled 
the above-mentioned criteria. 
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Written informed consent was obtained from adult patients and the parents or 
legal guardians of children. The study was approved by the ethics committees 
of all participating universities and hospitals. 
Methods 
To determine the role of low-frequency coding variants, we genotyped 93 
anthracycline-treated pediatric patients for the 247,870 variants on the Illumina 
HumanExome Beadchip and we evaluated single-variant associations with risk 
of chronic AIC and also performed gene-based testing and gene-enrichment 
and pathway analysis. Details of genotyping, statistical analyses and in silico 
prediction are provided in the Supplementary Information.     
RESULTS 
The demographic and clinical characteristics of the 93 anthracycline-treated 
pediatric cancer patients are shown in Table 1. Controls were significantly 
younger than cases at diagnosis (median age 5.1 and 10.4 years, respectively, 
P=0.004). Cumulative anthracycline dose was higher in cases than in controls 
(360 mg/m2 v 130 mg/m2 P<0.001), with doxorubicin being the most frequent 
anthracycline drug administered. There were fewer cases than controls 
diagnosed with leukemia (37% v 88%; P<0.001) but more with pediatric bone 
tumors (34% v 5.2% with osteosarcoma; P<0.001 and 29% v 6.9% with Ewing 
sarcoma; P=0.007). Regarding concomitant therapy, bleomycin was more often 
administered in cases than in controls (37% v 3.4%; P<0.001).  
Three patients (1 case and 2 controls) failed genotyping (call rate<0.95) and 7 
patients (4 cases and 3 controls) were excluded as ethnic outliers based on 
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inspection of plots of the two first principal components, leaving 83 patients for 
further analysis (Supplementary Figure 1).  
Single-variant associations 
Of the 247,870 variants on the array, 246,060 passed quality control and 53,136 
were polymorphic. After adjusting for age at diagnosis and cumulative 
anthracycline dose, none of these variants reached statistical significance after 
correcting for multiple testing (PFDR>0.05). 
Gene-based test 
We carried out gene-based analysis to further investigate the role of common 
and low-frequency variants in chronic AIC using the optimized sequence kernel 
association test (SKAT-O)24,25. We identified GPR35 (G protein-coupled 
receptor 35) as the gene most significantly associated with chronic AIC 
(P=4.0x10-6) and this association remained statistically significant after 
correction for multiple testing (corrected PFDR=0.02). Sensitivity analyses 
revealed variant rs12468485 (p.Thr253Met; c.758C>T) (MAF=0.04) made the 
greatest contribution to the observed association (Figure 1). The minor T allele 
of this variant was almost exclusively present in cases (MAFCASES=0.09 v 
MAFCONTROLS=0.009), with only one CT carrier among controls; no TT carriers 
were found in our series of anthracycline-treated pediatric cancer patients. The 
majority (67%) of cases carrying the CT genotype had an extreme chronic AIC 
phenotype: LV dysfunction, mostly symptomatic, evidenced after treatment with 
anthracycline doses well below the average for cases (CT cases=155mg/m2 v 
all other cases=360 mg/m2). To assess whether the model with the variant 
rs12468485 was more informative than the model with only non-genetic 
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variables (age at diagnosis and cumulative anthracycline dose) we used 
likelihood ratio tests. We obtained that the model including the variant 
rs12468485 and clinical factors provides a significant improvement over the 
model with only clinical variables (P=8.6x10-5). 
In order to evaluate the impact of the missense variant rs12468485 
(p.Thr253Met) on GPR35 protein structure or function, we applied six in silico 
prediction algorithms (Supplementary Table 1). p.Thr253Met was classified as 
pathogenic by PolyPhen-2 and MutPred, and was predicted by F-SNPs to a 
have a potentially regulatory role in splicing (Supplementary Table 1).  
GPR35 sequencing  
Due to the incomplete coverage in the exome array of coding variants in 
GPR35, we sequenced the exonic region of the gene in our series of 
anthracycline-treated pediatric cancer patients. We identified 17 coding 
variants, 6 of which had been genotyped on the exome array. Of the other 11, 2 
were in complete linkage disequilibrium with the variant rs12468485 and 2 had 
call rate<0.90 and were not analysed further. Of the remaining 7 coding variants 
identified (r2<0.36 with variant rs12468485) in GPR35 (Supplementary Table 2), 
4 were synonymous and 3 missense, and all had MAF<5%. 
Of these 7 new GPR35 variants, only rs35155396 was associated with risk 
independently of clinical factors (P=5.16x10-3), but not independently of 
rs12468485 (P=0.99).  
Gene-enrichment and pathway analysis  
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To gain further insight into the nature of the biological pathways impacting on 
AIC we performed a gene enrichment analysis using the bioinformatics tool 
DAVID based on the list of significant genes (P<0.05) with at least 3 variants 
identified in the SKAT-O analysis. Ten clusters with an enrichment score (ES) 
≥1.3 (indicating biological significance) were found (Supplementary Table 3). 
The cluster with the highest ES (3.1) revealed overrepresentation of 
glycoproteins, receptors, N-linked glycosylation sites and cell and plasma 
membrane components. No pathways were associated with AIC risk after 
multiple testing correction (P≥0.05). 
DISCUSSION 
Despite the demonstrated therapeutic effectiveness of anthracyclines in cancer 
treatment26, AIC continues to be a serious problem in survivors long after their 
treatments have ended and cancer has been cured1,2 and clinicians remain 
unable to accurately stratify patients into high or low-risk groups3,4. Considering 
that children are particularly vulnerable to the cardiotoxic effect of 
anthracyclines, even more than adults and/or at lower doses3,5, the identification 
of biomarkers of AIC risk in this specific group of patients seems crucial to 
maximize clinical benefit and minimize harm. 
In recent decades, candidate-gene studies and genome-wide association 
studies (GWAS) have been extensively applied to dissect the common genetic 
architecture of many complex traits27,28. Candidate-gene studies are limited by 
our understanding of the underlying molecular and biological mechanisms, and 
common variants discovered in GWAS studies explain only a small proportion 
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of the total heritability of complex traits29. New evidence has emerged over the 
past few years that additional heritability might be explained by low-frequency 
variants22,30, and in particular coding variants, which a priori are more likely to 
have larger impact on protein function31. Here, we have explored the 
contribution of low-frequency coding variants to susceptibility to AIC in children. 
To the best of our knowledge, this is the first study where this type of variation 
has been comprehensively analyzed using exome array data for children 
treated with anthracyclines and with long-term follow-up.   
Using standard single-variant association tests, none of the 246,060 variants 
analyzed was found to be statistically significantly associated with chronic AIC 
after correction for multiple comparisons; however, this result may be explained 
by low statistical power, due to small sample size and few patient cases32. We 
performed gene-based tests that have greater statistical power to detect 
associations with rare variation and can evaluate the cumulative effect of 
multiple genetic variants within a gene33. Some genes/regions may have a high 
proportion of causal variants and influence the phenotype in the same direction 
while others may have few causal variants or the causal variants may have 
different directions of association. Therefore, the use of methods optimal for 
both scenarios, such as the combined gene-based test SKAT-O applied in this 
study, is desirable24. Using this approach, we have identified GPR35 as the 
gene most significantly associated with chronic AIC in children. While the 
SKAT-O does not provide any parameter estimates, we assessed the individual 
contribution of variants within GPR35 and found that rs12468485, a missense 
low-frequency variant (p.Thr253Met), strongly associated with the most severe 
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cardiac manifestations, was most influential. Although in silico prediction 
algorithms yielded discrepant results, rs12468485 was predicted to a have a 
potentially regulatory role in splicing. Due to the incomplete coverage of coding 
variants on the exome array, we sequenced the coding region of GPR35 in our 
series of 93 anthracycline-treated pediatric cancer patients but we were unable 
to identify additional independent association signals at the gene.  
GPR35 belongs to the G-protein-coupled receptor family, which are membrane 
proteins mediating a wide range of physiological processes34. Although the 
exact functions of GPR35 are not known, several lines of evidence strongly 
suggest potential roles for this receptor in cardiac physiology and pathology. 
Sun et al35 were the first to report a cardiovascular role for GPR35, with a non-
synonymous single nucleotide polymorphism (rs3749172) significantly 
associated with the burden of coronary artery calcification. GPR35 was later 
found to be up-regulated in failing myocardium of patients with severe chronic 
heart, and in the same study GPR35 knock-out mice showed higher systolic 
blood36. More recently, GPR35 has been characterized as an early marker of 
progressive cardiac failure37. In vitro functional assays in cardiomyocytes 
demonstrated that GPR35 overexpression reduced cell viability and promoted 
morphological changes36,37. Several studies have linked GPR35 to inflammatory 
regulation38,39 and there is ample evidence to support the hypothesis that 
inflammation, as well as hypoxia, play a significant role in the pathogenesis and 
development of chronic cardiac complications, including cardiomyopathy40,41. 
These findings provide a possible explanation for the involvement of this 
receptor in cardiovascular disease. On the other hand, the cellular and 
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biological effects of GPR35 on cardiovascular pathophysiology could be largely 
mediated by downstream signaling pathways such as Gα13, Gαi/o and RhoA, 
following receptor activation42,43. Putative endogenous ligands of GPR35 have 
also been linked to cardiovascular disease in animals models44,45 and in 
patients with chronic advanced heart failure46 or acute myocardial infarction47. 
In conclusion, apart from the well-established clinical risk factors for AIC, such 
as age at diagnosis and cumulative anthracycline dose, GPR35, a gene with 
important roles in cardiac physiology and pathology, and in particular 
rs12468485, appear to be an independent risk factor for chronic AIC. We 
demonstrated that the inclusion of this variant significantly improved the risk 
prediction model and may enhance the ability of physicians to identify high-risk 
patients in clinical practice. However, further replication of the association and 
resequencing of the gene in larger cohorts of patients to identify additional 
GPR35 rare variants associated with risk of AIC are required. 
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FIGURE LEGENDS  
 
Figure 1. Contribution of individual GPR35 variants on statistical 
significances for the GPR35 gene. Top: genomic location of GPR35 displayed 
in the USCS Genome Browser. Exon location and amino acid substitution of 
each of the 7 coding polymorphic variants included in the Illumina 
HumanExome BeadChip array are depicted. Bottom: P-values for the GPR35 
association in SKAT-O gene-based tests after removing one variant (black line) 
at a time and recalculating the association. Grey line indicates the P-value for 
the GPR35 association with chronic AIC including all 7 coding variants 
(P=4.0x10-6). Abbreviations: Prot, protein. 
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Table 1. Patient clinical characteristics  
 Controls (N=58) Cases (N=35)  
Characteristic N %* N %* P 
Age at diagnosis (years)   0.004 
Median 5.1 10.4  
Range 1.4-16.9 1.2-21.1  
Gender     0.19 
Female 25 43 10 29  
Male 33 57 25 71  
Primary diagnosis (tumor type)      
Leukemia 51 88 13 37 <0.001 
Osteosarcoma 3 5.2 12 34 <0.001 
Ewing Sarcoma 4 6.9 10 29 0.007 
Family history of cardiovascular disease 3 5.2 4 17 0.21 
Radiotherapy involving the hearta 3 6.7 6 19 0.15 
Cumulative anthracycline dose (mg/m2)b     <0.001 
Mean 130 360  
Range 49.2-562 105-780  
≤ 200 43 74 8 23  
> 200 15 26 27 77  
Anthracycline type      
Doxorubicin 50 86 34 97 0.31 
Daunorubicin 8 14 1 2.9 0.15 
Epirubicin 5 8.6 - - 0.15 
Concomitant therapy      
Cyclophosphamide 55 95 27 77 0.06 
Vincristine 54 93 32 91 0.42 
Etoposide 14 24 13 37 0.24 
Bleomycin 2 3.4 13 37 <0.001 
Follow-up (years)     0.06 
Median 8.3 10.5  
Range 1-24.1 1-27.5  
Age, cumulative anthracycline dose and follow-up were analyzed by Wilcoxon-Mann-Whitney U test. Gender, tumor 
type, family history of cardiovascular disease, radiotherapy involving the heart, anthracycline type and concomitant 
therapy were analyzed by Fisher’s exact test. * Percentages are computed based on the total number of non-missing 
values. a Radiotherapy involving the heart includes mediastinal and mantle radiation and total body irradiation. b 
Cumulative anthracycline dose was calculated using doxorubicin equivalents. Bold fold indicates statistically 
significant P-values (P<0.05).  
 

  
 
 
 
 
 
 
 
 
 
Supplementary Table 1. In silico prediction of the functional effect of rs12468485 (p.Thr253Met) 
 
 
 
F-SNP prediction 
 
Variant SIFT prediction 
Polyphen-2 
prediction 
MutPred 
prediction 
SNPs&GO 
Prediction 
PON-P2 
prediction 
PredictSNP 
prediction 
ESEfinder 
prediction 
ESRSearch 
prediction 
PESX 
prediction 
RESCUE_ESE 
prediction 
rs12468485 
(p.Thr253Met) 
Tolerated Possibly  damaging Pathogenic Neutral Neutral Neutral Changed Changed Changed Changed 
Bold type indicates a likely pathogenic effect or a change in splicing predicted by each in silico algorithm. Predictions are on GPR35 protein with Uniprot identifier Q9HC97 
 Supplementary Table 2. Additional GPR35 coding variants identified by sequencing 
Variant Position MAF Function 
rs138283952 chr2:241569810 0.007 Synonymous 
rs142918765 chr2:241570284 0.007 Synonymous 
rs147336244 chr2:241569669 0.006 Synonymous 
rs34778053 chr2:241569742 0.01 Missense (p.Arg156Ser) 
rs35155396 chr2:241569585 0.02 Synonymous 
rs61734453 chr2:241569745 0.006 Missense (p.Gly157Arg) 
rs763867971 chr2:241570132 0.007 Missense (p.Arg286Cys) 
Chromosome positions are based on Genome Reference Consortium Human Build 37 
(GRCh37/hg19). Abbreviations: MAF, minor allele frequency 
 Supplementary Table 3. Functional Annotation Clustering from the DAVID tool (Enrichment score ≥ 1.3). 
Annotation cluster 1 Enrichment score: 3.1 
Category Term Count P Genes P-Benjamini 
SP_PIR_KEYWORDS Glycoprotein 125 9.2x10-7 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, 
CHRNA9, CD44, LRRC52, PI16, ODZ3, GRID1, CLCA1, OR10S1, 
SLCO4A1, SPARCL1, PTPRN2, PLXNB2, CDHR2, SLC22A20, 
HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, CHGB, DST, FGFR4, 
PANX1, AMTN, OR2T1, KEL, ENPP3, ITGAM, CRB2, P2RY2, 
ENTPD7, BAI2, SFTPD, B3GNT3, EGF, GCNT1, ADAM28, 
EPB41, ITGA3, OR5AC2, GPR35, SLC4A11, P2RX3, NOTCH4, 
TSC2, OR51A7, UTP14C, COL20A1, CHRNG, ARSB, ARSD, 
CLSTN2, CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, 
C14ORF135, SMPDL3A, NMUR2, POMT1, OR6P1, ANO2, CTBS, 
USH2A, OR2AE1, OR10J1, NCR3, CD86, TNFRSF10C, CLECL1, 
TAS2R19, ZPBP2, GRM6, ERN1, KCNH8, C4ORF29, PLA2G3, 
WFIKKN2, LRRC32, CPN2, NUP214, C1QTNF6, FCN2, COL6A2, 
FUT3, UGT2A1, COL6A1, CCBP2, HRG, PLA2R1, DKKL1, 
SLC39A4, QSOX1, SOAT1, TMC6, MOGAT1, CES1, OR8G2, 
FBN1, FUCA2, MAN1C1, COL5A1, PLG, OR51M1, CDH13, 
PROM2, GPR110, SLC17A2, ANXA11, GPR113, MEP1B, 
GPR111, MEGF6, ABCC8, GFRA2, ABCC6, GPR116 
1.7x10-4 
UP_SEQ_FEATURE N-linked glycosylation sites (GlcNAc...) 116 1.7x10
-5 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, 
CHRNA9, CD44, LRRC52, PI16, ODZ3, GRID1, CLCA1, OR10S1, 
SPARCL1, SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, 
HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, DST, FGFR4, 
PANX1, OR2T1, KEL, ENPP3, ITGAM, CRB2, P2RY2, ENTPD7, 
BAI2, SFTPD, B3GNT3, EGF, GCNT1, ADAM28, ITGA3, OR5AC2, 
GPR35, SLC4A11, P2RX3, NOTCH4, OR51A7, UTP14C, 
COL20A1, CHRNG, ARSB, ARSD, CLSTN2, CLSTN3, 
TMEM161A, CDSN, FCRL3, RSPO4, C14ORF135, SMPDL3A, 
NMUR2, POMT1, OR6P1, ANO2, CTBS, USH2A, OR2AE1, 
1.2x10-2 
OR10J1, NCR3, CD86, CLECL1, TAS2R19, ZPBP2, GRM6, 
ERN1, KCNH8, C4ORF29, PLA2G3, WFIKKN2, LRRC32, CPN2, 
C1QTNF6, FCN2, COL6A2, FUT3, UGT2A1, COL6A1, CCBP2, 
HRG, PLA2R1, DKKL1, SLC39A4, QSOX1, TMC6, MOGAT1, 
CES1, OR8G2, FBN1, FUCA2, MAN1C1, PLG, OR51M1, CDH13, 
PROM2, GPR110, SLC17A2, GPR113, MEP1B, GPR111, MEGF6, 
ABCC8, GFRA2, ABCC6, GPR116 
SP_PIR_KEYWORDS Receptor 55 3.3x10-5 
TRPV3, GRIN3B, OR8S1, FCRL3, LPHN2, OR4D2, CHRNA9, 
CD44, NMUR2, OR6P1, GRID1, OR10S1, PLXNB2, PTPRN2, 
PPARGC1A, OR2AE1, OR10J1, TRPM2, NCR3, TNFRSF10C, 
CD86, TAS2R19, LILRB4, GRM6, LRP11, GPR50, OR8B4, 
FGFR4, OR2T1, PAQR7, ITGAM, P2RY2, BAI2, CCBP2, PLA2R1, 
TRIP11, OR8G2, ITGA3, PTPN12, OR5AC2, OR51M1, GPR35, 
EPS8, GPR110, P2RX3, NOTCH4, GPR113, GPR111, MS4A10, 
ABL1, ABCC8, OR51A7, GFRA2, CHRNG, GPR116 
2.5x10-3 
GOTERM_CC_FAT Plasma membrane 107 5.3x10-5 
LMO7, OR8S1, GRIN3B, LPHN2, OR4D2, CHRNA9, CD44, 
WNK4, GRID1, CLCA1, OR10S1, MYH1, PTPRN2, CDHR2, HLA-
C, CTNNA3, LILRB4, GPR50, OR8B4, KBTBD10, DST, SNTG2, 
HDLBP, FGFR4, PANX1, AMTN, OR2T1, KEL, ENPP3, MAP4K2, 
PAQR7, ITGAM, KCNS3, CRB2, PLCH2, P2RY2, TRO, BAI2, 
B3GNT3, EGF, SLC28A3, ADAM28, EPB41, LPP, KCNB1, ITGA3, 
OR5AC2, GPR35, SLC4A11, EPS8, P2RX3, NOTCH4, TSC2, 
MAP7, OR51A7, PLA2G4E, CHRNG, TM7SF4, CLSTN2, CLSTN3, 
KCNJ12, CDSN, FCRL3, NMUR2, SDPR, OR6P1, KCNG4, RHOF, 
USH2A, OR2AE1, TRPM2, OR10J1, NCR3, CD86, TNFRSF10C, 
CLECL1, SLC26A9, GRM6, PLA2G3, NKD2, LRRC32, TAP2, 
COL6A2, COL6A1, CCBP2, PLA2R1, SLC39A4, OR8G2, 
PPP1R9B, COG4, OR51M1, CDH13, PROM2, ERBB2IP, NRAP, 
GPR110, SLC17A2, GPR113, MEP1B, ANXA13, GPR111, SYNM, 
TAPBPL, ABCC8, GFRA2, ABCC6, GPR116 
1.5x10-2 
UP_SEQ_FEATURE 
 
Topological domain: 
cytoplasmic 
94 2.3x10-4 
TM7SF4, CLSTN2, CLSTN3, TRPV3, TMEM161A, GRIN3B, 
OR8S1, KCNJ12, FCRL3, LPHN2, OR4D2, CHRNA9, CD44, 
NMUR2, LRRC52, OR6P1, ANO2, PI16, KCNG4, ODZ3, USH2A, 
GRID1, OR10S1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
OR2AE1, PNPLA3, OR10J1, TRPM2, NCR3, CD86, TAS2R19, 
CLECL1, LILRB4, LRP11, GRM6, ERN1, GPR50, KCNH8, OR8B4, 
0.078 
 FGFR4, PANX1, OR2T1, LRRC32, ENPP3, KEL, PAQR7, ITGAM, 
KCNS3, CRB2, P2RY2, ENTPD7, TAP2, BAI2, FUT3, UGT2A1, 
B4GALNT3, CCBP2, B3GNT3, PLA2R1, EGF, SLC39A4, GCNT1, 
SLC28A3, ADAM28, TMC6, OR8G2, KCNB1, SPPL2A, ITGA3, 
MAN1C1, OR5AC2, CPT1A, OR51M1, GPR35, SLC4A11, 
PROM2, PLSCR4, GPR110, P2RX3, NOTCH4, GPR113, MEP1B, 
MS4A10, GPR111, TAPBPL, OR51A7, ABCC8, ABCC6, GPR116, 
CHRNG 
SP_PIR_KEYWORDS Cell membrane 65 5.6x10-4 
TM7SF4, CLSTN2, CLSTN3, GRIN3B, OR8S1, FCRL3, LPHN2, 
OR4D2, CHRNA9, NMUR2, OR6P1, ANO2, RHOF, KCNG4, 
USH2A, GRID1, CLCA1, OR10S1, CDHR2, HLA-C, OR2AE1, 
OR10J1, NCR3, TNFRSF10C, CLECL1, LILRB4, GRM6, GPR50, 
OR8B4, PLA2G3, SNTG2, NKD2, PANX1, OR2T1, KEL, MAP4K2, 
PAQR7, KCNS3, CRB2, P2RY2, PLCH2, BAI2, CCBP2, PLA2R1, 
SLC39A4, ADAM28, OR8G2, LPP, OR5AC2, OR51M1, CDH13, 
GPR35, PROM2, SLC4A11, GPR110, NOTCH4, GPR113, 
ANXA13, GPR111, MAP7, TAPBPL, OR51A7, GFRA2, CHRNG, 
GPR116 
0.030 
UP_SEQ_FEATURE Topological domain: extracellular 76 1.1x10
-3 
LSTN2, CLSTN3, TRPV3, TMEM161A, GRIN3B, OR8S1, KCNJ12, 
FCRL3, LPHN2, OR4D2, CHRNA9, CD44, NMUR2, LRRC52, 
OR6P1, ANO2, PI16, ODZ3, USH2A, GRID1, OR10S1, PLXNB2, 
PTPRN2, CDHR2, HLA-C, SLC22A20, OR2AE1, TRPM2, OR10J1, 
NCR3, CD86, TAS2R19, CLECL1, LILRB4, LRP11, GRM6, 
GPR50, OR8B4, FGFR4, PANX1, OR2T1, LRRC32, ENPP3, KEL, 
PAQR7, ITGAM, CRB2, P2RY2, BAI2, UGT2A1, CCBP2, PLA2R1, 
SLC39A4, EGF, SLC28A3, ADAM28, OR8G2, ITGA3, OR5AC2, 
OR51M1, GPR35, SLC4A11, PROM2, PLSCR4, GPR110, P2RX3, 
NOTCH4, GPR113, MEP1B, GPR111, MS4A10, ABCC8, OR51A7, 
CHRNG, GPR116, ABCC6 
0.245 
SP_PIR_KEYWORDS Transmembrane 
 
116 
 
 
0.017 
 
OR8S1, GRIN3B, SLC7A4, SLC26A10, LPHN2, OR4D2, CHRNA9, 
CD44, LRRC52, PI16, ODZ3, GRID1, SMCR7, OR10S1, 
SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
PPP1R3A, PNPLA3, RNF133, LILRB4, LRP11, GPR50, OR8B4, 
AKAP1, FGFR4, PANX1, OR2T1, SLC38A8, KEL, ENPP3, 
PAQR7, ITGAM, KCNS3, CRB2, P2RY2, ENTPD7, BAI2, B3GNT3, 
EGF, GCNT1, SLC28A3, ADAM28, KCNB1, SPPL2A, ITGA3, 
0.37 
OR5AC2, GPR35, SLC4A11, P2RX3, NOTCH4, MS4A10, 
OR51A7, UTP14C, CHRNG, LRIT3, TM7SF4, CLSTN2, CLSTN3, 
TRPV3, TMEM161A, KCNJ12, FCRL3, C14ORF135, NMUR2, 
POMT1, OR6P1, ANO2, KCNG4, USH2A, OR2AE1, TRPM2, 
OR10J1, NCR3, CD86, CLECL1, TAS2R19, GRM6, SLC26A9, 
ERN1, KCNH8, C6ORF191, LRRC32, C2ORF85, TAP2, FUT3, 
UGT2A1, B4GALNT3, ILVBL, CCBP2, PLA2R1, SLC39A4, 
QSOX1, SOAT1, TMC6, SOAT2, MOGAT1, OR8G2, MAN1C1, 
CPT1A, OR51M1, PROM2, PLSCR4, CYP26C1, GPR110, 
SLC17A2, GPR113, MEP1B, GPR111, TAPBPL, ABCC8, ABCC6, 
GPR116 
UP_SEQ_FEATURE Transmembrane 
region 
 
116 
 
 
0.019 
 
OR8S1, GRIN3B, SLC7A4, SLC26A10, LPHN2, OR4D2, CHRNA9, 
CD44, LRRC52, PI16, ODZ3, GRID1, SMCR7, OR10S1, 
SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
PPP1R3A, PNPLA3, RNF133, LILRB4, LRP11, GPR50, OR8B4, 
FGFR4, PANX1, OR2T1, SLC38A8, KEL, ENPP3, PAQR7, 
ITGAM, KCNS3, CRB2, P2RY2, ENTPD7, BAI2, B3GNT3, EGF, 
GCNT1, SLC28A3, ADAM28, KCNB1, SPPL2A, ITGA3, OR5AC2, 
GPR35, SLC4A11, P2RX3, NOTCH4, MS4A10, OR51A7, 
UTP14C, CHRNG, LRIT3, TM7SF4, CLSTN2, CLSTN3, TRPV3, 
TMEM161A, KCNJ12, FCRL3, C14ORF135, NMUR2, POMT1, 
OR6P1, ANO2, KCNG4, USH2A, OR2AE1, TRPM2, OR10J1, 
NCR3, CD86, CLECL1, TAS2R19, GRM6, SLC26A9, ERN1, 
KCNH8, C6ORF191, LRRC32, C2ORF85, TAP2, FUT3, UGT2A1, 
B4GALNT3, ILVBL, CCBP2, PLA2R1, SLC39A4, QSOX1, SOAT1, 
TMC6, SOAT2, MOGAT1, OR8G2, MAN1C1, CPT1A, OR51M1, 
PROM2, PLSCR4, CYP26C1, GPR110, SLC17A2, GPR113, 
MEP1B, GPR111, TAPBPL, ABCC8, ABCC6, GPR116 
0.802 
 
SP_PIR_KEYWORDS 
 
Membrane 140 
 
0.029 
 
OR8S1, GRIN3B, SLC26A10, SLC7A4, LPHN2, OR4D2, CHRNA9, 
CD44, LRRC52, PI16, ODZ3, GRID1, SMCR7, CLCA1, OR10S1, 
SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
PPP1R3A, PNPLA3, RNF133, PITPNM3, LILRB4, LRP11, USO1, 
GPR50, OR8B4, AKAP1, SNTG2, FGFR4, PANX1, SLC38A8, 
OR2T1, KEL, ENPP3, MAP4K2, PAQR7, ITGAM, KCNS3, CRB2, 
PLCH2, P2RY2, ENTPD7, BAI2, B3GNT3, EGF, GCNT1, 
SLC28A3, ADAM28, LPP, KCNB1, SPPL2A, ITGA3, OR5AC2, 
0.41 
 
GPR35, SLC4A11, P2RX3, TSC2, NOTCH4, MS4A10, MAP7, 
ABL1, OR51A7, PLA2G4E, UTP14C, CHRNG, UQCRC2, LRIT3, 
TM7SF4, CLSTN2, CLSTN3, TRPV3, TMEM161A, KCNJ12, 
FCRL3, C14ORF135, SDPR, POMT1, NMUR2, OR6P1, ANO2, 
KCNG4, RHOF, USH2A, OR2AE1, TRPM2, OR10J1, NCR3, 
TNFRSF10C, CD86, CLECL1, TAS2R19, GRM6, SLC26A9, ERN1, 
KCNH8, PLA2G3, C6ORF191, NKD2, LRRC32, NLRX1, 
C2ORF85, TAP2, COL6A2, FUT3, UGT2A1, B4GALNT3, ILVBL, 
CCBP2, PLA2R1, SLC39A4, QSOX1, TRIP11, SOAT1, SOAT2, 
TMC6, MOGAT1, OR8G2, MAN1C1, CPT1A, CDH13, OR51M1, 
COG4, PROM2, CYP26C1, PLSCR4, GPR110, SLC17A2, 
GPR113, MEP1B, ANXA13, GPR111, TAPBPL, ABCC8, GFRA2, 
ABCC6, GPR116 
GOTERM_CC_FAT 
 
 
Integral to membrane 
 
123 
0.036 
 
OR8S1, GRIN3B, SLC7A4, SLC26A10, LPHN2, OR4D2, CHRNA9, 
CD44, LRRC52, PI16, ODZ3, GRID1, SMCR7, CLCA1, OR10S1, 
SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
PPP1R3A, PNPLA3, RNF133, PITPNM3, LILRB4, LRP11, GPR50, 
OR8B4, AKAP1, FGFR4, PANX1, OR2T1, SLC38A8, KEL, ENPP3, 
PAQR7, ITGAM, KCNS3, CRB2, TRO, P2RY2, ENTPD7, BAI2, 
B3GNT3, EGF, GCNT1, SLC28A3, ADAM28, KCNB1, SPPL2A, 
ITGA3, OR5AC2, GPR35, SLC4A11, EPS8, P2RX3, NOTCH4, 
MS4A10, OR51A7, UTP14C, CHRNG, LRIT3, TM7SF4, CLSTN2, 
CLSTN3, TRPV3, TMEM161A, KCNJ12, FCRL3, C14ORF135, 
NMUR2, POMT1, OR6P1, ANO2, KCNG4, USH2A, OR2AE1, 
TRPM2, OR10J1, NCR3, CD86, TNFRSF10C, CLECL1, TAS2R19, 
NUP205, GRM6, SLC26A9, ERN1, KCNH8, C6ORF191, LRRC32, 
C2ORF85, NUP214, TAP2, FUT3, UGT2A1, B4GALNT3, ILVBL, 
CCBP2, PLA2R1, SLC39A4, QSOX1, SOAT1, TMC6, SOAT2, 
MOGAT1, OR8G2, MAN1C1, CPT1A, OR51M1, PROM2, 
CYP26C1, PLSCR4, GPR110, SLC17A2, GPR113, MEP1B, 
GPR111, TAPBPL, ABCC8, ABCC6, GPR116 
0.58 
 
GOTERM_CC_FAT Intrinsic to membrane 125 0.059 
OR8S1, GRIN3B, SLC7A4, SLC26A10, LPHN2, OR4D2, CHRNA9, 
CD44, LRRC52, PI16, ODZ3, GRID1, SMCR7, CLCA1, OR10S1, 
SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, HLA-C, 
PPP1R3A, PNPLA3, RNF133, PITPNM3, LILRB4, LRP11, GPR50, 
OR8B4, AKAP1, FGFR4, PANX1, OR2T1, SLC38A8, KEL, ENPP3, 
0.58 
PAQR7, ITGAM, KCNS3, CRB2, TRO, P2RY2, ENTPD7, BAI2, 
B3GNT3, EGF, GCNT1, SLC28A3, ADAM28, KCNB1, SPPL2A, 
ITGA3, OR5AC2, GPR35, SLC4A11, EPS8, P2RX3, NOTCH4, 
MS4A10, OR51A7, UTP14C, CHRNG, LRIT3, TM7SF4, CLSTN2, 
CLSTN3, TRPV3, TMEM161A, KCNJ12, FCRL3, C14ORF135, 
NMUR2, POMT1, OR6P1, ANO2, KCNG4, USH2A, OR2AE1, 
TRPM2, OR10J1, NCR3, CD86, TNFRSF10C, CLECL1, TAS2R19, 
NUP205, GRM6, SLC26A9, ERN1, KCNH8, C6ORF191, LRRC32, 
C2ORF85, NUP214, TAP2, FUT3, UGT2A1, B4GALNT3, ILVBL, 
CCBP2, PLA2R1, SLC39A4, QSOX1, SOAT1, TMC6, SOAT2, 
MOGAT1, OR8G2, MAN1C1, CPT1A, OR51M1, CDH13, PROM2, 
CYP26C1, PLSCR4, GPR110, SLC17A2, GPR113, MEP1B, 
GPR111, TAPBPL, ABCC8, GFRA2, ABCC6, GPR116 
Annotation cluster 2 Enrichment score: 2.35 
Category Term Count P Genes P-Benjamini 
UP_SEQ_FEATURE Domain:GPS 6 6.3x10
-4 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.17 
INTERPRO GPS 6 8.8x10
-4 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.45 
PIR_SUPERFAMILY 
PIRSF800007:secretin 
receptor-like G 
protein-coupled 
receptors 
6 9x10
-4 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.13 
SMART GPS 6 1.3x10
-3 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.21 
INTERPRO GPCR, family 2, secretin-like 6 
2.1x10-3 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.51 
INTERPRO GPCR, family 2, secretin-like, 
conserved site 
6 2.6x10
-3 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116 0.44 
INTERPRO GPCR, family 2-like 6 6.3x10
-3 LPHN2, GPR110, GPR113, BAI2, GPR111, GPR116      0.65 
GOTERM_BP_FAT Neuropeptide 
signaling pathway 7 0.011 LPHN2, GPR110, NMUR2, GPR113, BAI2, GPR111, GPR116 1.00 
INTERPRO GPCR, family 2, 
extracellular region 3 0.10 LPHN2, GPR113, BAI2 0.95 
SMART HormR 3 0.12 LPHN2, GPR113, BAI2 0.94 
Annotation cluster 3 Enrichment score: 2.19 
Category Term Count P Genes P-Benjamini 
SP_PIR_KEYWORDS Glycoprotein 125 9.2x10-7 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, 
CHRNA9, CD44, LRRC52, PI16, ODZ3, GRID1, CLCA1, 
OR10S1, SLCO4A1, SPARCL1, PTPRN2, PLXNB2, CDHR2, 
SLC22A20, HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, CHGB, 
DST, FGFR4, PANX1, AMTN, OR2T1, KEL, ENPP3, ITGAM, 
CRB2, P2RY2, ENTPD7, BAI2, SFTPD, B3GNT3, EGF, GCNT1, 
ADAM28, EPB41, ITGA3, OR5AC2, GPR35, SLC4A11, P2RX3, 
NOTCH4, TSC2, OR51A7, UTP14C, COL20A1, CHRNG, ARSB, 
ARSD, CLSTN2, CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, 
C14ORF135, SMPDL3A, NMUR2, POMT1, OR6P1, ANO2, 
CTBS, USH2A, OR2AE1, OR10J1, NCR3, CD86, TNFRSF10C, 
CLECL1, TAS2R19, ZPBP2, GRM6, ERN1, KCNH8, C4ORF29, 
PLA2G3, WFIKKN2, LRRC32, CPN2, NUP214, C1QTNF6, 
FCN2, COL6A2, FUT3, UGT2A1, COL6A1, CCBP2, HRG, 
PLA2R1, DKKL1, SLC39A4, QSOX1, SOAT1, TMC6, MOGAT1, 
CES1, OR8G2, FBN1, FUCA2, MAN1C1, COL5A1, PLG, 
OR51M1, CDH13, PROM2, GPR110, SLC17A2, ANXA11, 
GPR113, MEP1B, GPR111, MEGF6, ABCC8, GFRA2, ABCC6, 
GPR116
1.7x10-4 
UP_SEQ_FEATURE N-linked glycosylation sites (GlcNAc...) 116 1.7x10
-5 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, 
CHRNA9, CD44, LRRC52, PI16, ODZ3, GRID1, CLCA1, 
OR10S1, SPARCL1, SLCO4A1, PTPRN2, PLXNB2, CDHR2, 
SLC22A20, HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, DST, 
1.2x10-2 
FGFR4, PANX1, OR2T1, KEL, ENPP3, ITGAM, CRB2, P2RY2, 
ENTPD7, BAI2, SFTPD, B3GNT3, EGF, GCNT1, ADAM28, 
ITGA3, OR5AC2, GPR35, SLC4A11, P2RX3, NOTCH4, 
OR51A7, UTP14C, COL20A1, CHRNG, ARSB, ARSD, CLSTN2, 
CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, C14ORF135, 
SMPDL3A, NMUR2, POMT1, OR6P1, ANO2, CTBS, USH2A, 
OR2AE1, OR10J1, NCR3, CD86, CLECL1, TAS2R19, ZPBP2, 
GRM6, ERN1, KCNH8, C4ORF29, PLA2G3, WFIKKN2, 
LRRC32, CPN2, C1QTNF6, FCN2, COL6A2, FUT3, UGT2A1, 
COL6A1, CCBP2, HRG, PLA2R1, DKKL1, SLC39A4, QSOX1, 
TMC6, MOGAT1, CES1, OR8G2, FBN1, FUCA2, MAN1C1, 
PLG, OR51M1, CDH13, PROM2, GPR110, SLC17A2, GPR113, 
MEP1B, GPR111, MEGF6, ABCC8, GFRA2, ABCC6, GPR116 
SP_PIR_KEYWORDS Signal 83 6.1x10-3 
ARSB, ARSD, CLSTN2, CLSTN3, TMEM161A, FSTL4, 
GRIN3B, CDSN, MMRN2, FCRL3, APOA4, LPHN2, RSPO4, 
CHRNA9, CD44, SMPDL3A, LRRC52, PI16, CTBS, USH2A, 
GRID1, CLCA1, SPARCL1, PLXNB2, PTPRN2, CDHR2, HLA-C, 
CECR5, NCR3, TNFAIP6, AMBN, TNFRSF10C, CD86, ZPBP2, 
TXNDC5, LILRB4, LRP11, GRM6, ERN1, C4ORF29, PLA2G3, 
CHGB, WFIKKN2, FGFR4, AMTN, LRRC32, ITGAM, CPN2, 
C1QTNF6, CRB2, FCN2, SFTPD, BAI2, COL6A2, UGT2A1, 
COL6A1, HRG, PLA2R1, SLC39A4, DKKL1, EGF, QSOX1, 
DEFB119, ADAM28, FGFBP3, CES1, FBN1, ITGA3, FUCA2, 
COL5A1, PLG, CDH13, PROM2, GPR110, NOTCH4, GPR113, 
MEP1B, TAPBPL, MEGF6, GFRA2, COL20A1, GPR116, 
CHRNG       
0.23 
UP_SEQ_FEATURE Signal peptide 83 7.2x10-3 
ARSB, ARSD, CLSTN2, CLSTN3, TMEM161A, FSTL4, 
GRIN3B, CDSN, MMRN2, FCRL3, APOA4, LPHN2, RSPO4, 
CHRNA9, CD44, SMPDL3A, LRRC52, PI16, CTBS, USH2A, 
GRID1, CLCA1, SPARCL1, PLXNB2, PTPRN2, CDHR2, HLA-C, 
CECR5, NCR3, TNFAIP6, AMBN, TNFRSF10C, CD86, ZPBP2, 
TXNDC5, LILRB4, LRP11, GRM6, ERN1, C4ORF29, PLA2G3, 
CHGB, WFIKKN2, FGFR4, AMTN, LRRC32, ITGAM, CPN2, 
C1QTNF6, CRB2, FCN2, SFTPD, BAI2, COL6A2, UGT2A1, 
COL6A1, HRG, PLA2R1, SLC39A4, DKKL1, EGF, QSOX1, 
DEFB119, ADAM28, FGFBP3, CES1, FBN1, ITGA3, FUCA2, 
0.61 
COL5A1, PLG, CDH13, PROM2, GPR110, NOTCH4, GPR113, 
MEP1B, TAPBPL, MEGF6, GFRA2, COL20A1, GPR116, 
CHRNG   
GOTERM_CC_FAT Extracellular region part 28 0.052 
DLBP, AMTN, MMRN2, APOA4, CD44, SMPDL3A, FCN2, 
COL6A2, SFTPD, COL6A1, PLA2R1, EGF, DKKL1, QSOX1, 
USH2A, CLCA1, SPARCL1, FBN1, COL5A1, PLG, CDH13, 
AMBN, ERBB2IP, NOTCH4, MEP1B, PLA2G3, DST, COL20A1 
0.59 
SP_PIR_KEYWORDS Disulfide bond 67 0.10 
ARSB, LRIT3, FSTL4, OR8S1, MMRN2, FCRL3, LPHN2, 
RSPO4, OR4D2, CHRNA9, CD44, NMUR2, OR6P1, ODZ3, 
USH2A, OR10S1, SPARCL1, HLA-C, OR2AE1, OR10J1, NCR3, 
TNFAIP6, TNFRSF10C, CD86, TXNDC5, LILRB4, LRP11, 
ERN1, GPR50, OR8B4, PLA2G3, CHGB, WFIKKN2, FGFR4, 
OR2T1, ENPP3, KEL, CPN2, ITGAM, CRB2, FCN2, P2RY2, 
SFTPD, BAI2, HRG, CCBP2, PLA2R1, EGF, GCNT1, DEFB119, 
ADAM28, FGFBP3, CES1, OR8G2, FBN1, ITGA3, OR5AC2, 
PLG, OR51M1, GPR35, NOTCH4, MEP1B, TAPBPL, MEGF6, 
OR51A7, CHRNG, GPR116 
0.67 
GOTERM_CC_FAT Extracellular region 49 0.12 
WFIKKN2, HDLBP, AMTN, TUFT1, ENPP3, FSTL4, CDSN, 
CPN2, MMRN2, APOA4, RSPO4, C1QTNF6, CD44, CRB2, 
SMPDL3A, FCN2, SFTPD, COL6A2, COL6A1, HRG, PLA2R1, 
PI16, EGF, CASP1, DKKL1, QSOX1, USH2A, DEFB119, 
FGFBP3, ADAM28, CLCA1, SPARCL1, FBN1, HLA-C, FUCA2, 
COL5A1, PLG, CDH13, AMBN, ERBB2IP, ZPBP2, NOTCH4, 
MEP1B, C4ORF29, PLA2G3, MEGF6, DST, CHGB, COL20A1 
0.76 
SP_PIR_KEYWORDS Secreted 39 0.19 
WFIKKN2, AMTN, TUFT1, ENPP3, FSTL4, CDSN, CPN2, 
MMRN2, APOA4, RSPO4, C1QTNF6, CRB2, SMPDL3A, FCN2, 
COL6A2, SFTPD, COL6A1, HRG, PLA2R1, DKKL1, QSOX1, 
USH2A, DEFB119, FGFBP3, ADAM28, CLCA1, SPARCL1, 
FBN1, HLA-C, FUCA2, COL5A1, PLG, AMBN, ZPBP2, 
C4ORF29, PLA2G3, MEGF6, CHGB, COL20A1 
0.77 
GOTERM_CC_FAT Extracellular space 18 0.23 
HDLBP, CLCA1, FBN1, PLG, MMRN2, APOA4, CDH13, 
SMPDL3A, FCN2, NOTCH4, SFTPD, MEP1B, PLA2G3, 
PLA2R1, EGF, DKKL1, QSOX1, COL20A1    
0.86 
Annotation cluster 4 Enrichment score: 1.79 
Category Term Count P Genes P-Benjamini 
GOTERM_CC_FAT Plasma membrane part 64 2.2x10
-3 
LMO7, GRIN3B, KCNJ12, CDSN, CHRNA9, CD44, WNK4, 
SDPR, RHOF, KCNG4, GRID1, CLCA1, MYH1, PTPRN2, 
CDHR2, HLA-C, CTNNA3, OR10J1, TRPM2, NCR3, 
TNFRSF10C, CD86, GRM6, SLC26A9, GPR50, KBTBD10, 
DST, SNTG2, FGFR4, PANX1, AMTN, LRRC32, ENPP3, KEL, 
ITGAM, KCNS3, P2RY2, TRO, TAP2, CCBP2, B3GNT3, 
PLA2R1, SLC39A4, LPP, KCNB1, ITGA3, PPP1R9B, COG4, 
CDH13, GPR35, SLC4A11, ERBB2IP, EPS8, NRAP, P2RX3, 
TSC2, SLC17A2, NOTCH4, MEP1B, MAP7, SYNM, PLA2G4E, 
CHRNG, ABCC6       
0.26 
GOTERM_CC_FAT Integral to plasma membrane 34 0.039 
FGFR4, LRRC32, KEL, ENPP3, GRIN3B, ITGAM, KCNS3, 
CHRNA9, CD44, P2RY2, TAP2, TRO, B3GNT3, CCBP2, 
PLA2R1, KCNG4, CLCA1, PTPRN2, KCNB1, ITGA3, HLA-C, 
TRPM2, OR10J1, NCR3, GPR35, TNFRSF10C, EPS8, P2RX3, 
NOTCH4, SLC17A2, GRM6, MEP1B, GPR50, CHRNG   
0.55 
GOTERM_CC_FAT Intrinsic to plasma membrane 34 0.050 
FGFR4, LRRC32, KEL, ENPP3, GRIN3B, ITGAM, KCNS3, 
CHRNA9, CD44, P2RY2, TAP2, TRO, B3GNT3, CCBP2, 
PLA2R1, KCNG4, CLCA1, PTPRN2, KCNB1, ITGA3, HLA-C, 
TRPM2, OR10J1, NCR3, GPR35, TNFRSF10C, EPS8, P2RX3, 
NOTCH4, SLC17A2, GRM6, MEP1B, GPR50, CHRNG        
0.60 
Annotation cluster 5 Enrichment score: 1.62 
Category Term Count P Genes P-Benjamini 
SP_PIR_KEYWORDS Cell adhesion 16 0.019 
CLSTN2, AMTN, CLSTN3, LPP, CDHR2, ITGA3, ITGAM, 
CTNNA3, CDH13, TNFAIP6, CD44, TRO, COL6A2, COL6A1, 
ABL1, DST    
0.36 
GOTERM_BP_FAT Cell-cell adhesion 12 0.025 OA4, CDH13, CLSTN2, CD44, CLSTN3, TRO, CDHR2, COL6A2, LMO7, CDSN, ITGAM, CTNNA3 1.00 
GOTERM_BP_FAT Biological adhesion 23 0.026 
CLSTN2, AMTN, CLSTN3, LPP, CDHR2, LMO7, ITGA3, CDSN, 
COL5A1, ITGAM, CTNNA3, APOA4, CDH13, TNFAIP6, AMBN, 
ERBB2IP, CD44, TRO, COL6A2, COL6A1, ABL1, DST, 
1.00 
COL20A1 
GOTERM_BP_FAT Cell adhesion 23 0.027 
CLSTN2, AMTN, CLSTN3, LPP, CDHR2, LMO7, ITGA3, CDSN, 
COL5A1, ITGAM, CTNNA3, APOA4, CDH13, TNFAIP6, AMBN, 
ERBB2IP, CD44, TRO, COL6A2, COL6A1, ABL1, DST, 
COL20A1 
1.00 
Annotation cluster 6 Enrichment score: 1.61 
Category Term Count P Genes P-Benjamini 
INTERPRO Kinesin, motor region, conserved site 5 9.5x10
-3 KIF1B, KIF6, KIF17, CENPE, KIF16B 0.66 
INTERPRO Kinesin, motor region 5 9.5x10-3 KIF1B, KIF6, KIF17, CENPE, KIF16B 0.66 
UP_SEQ_FEATURE Domain: kinesin-motor 5 9.7x10-3 KIF1B, KIF6, KIF17, CENPE, KIF16B 0.69 
SMART KISc 5 0.013 KIF1B, KIF6, KIF17, CENPE, KIF16B 0.68 
SP_PIR_KEYWORDS Motor protein 8 0.015 DNALI1, KIF1B, DNAI1, MYH1, KIF6, KIF17, CENPE, KIF16B 0.35 
GOTERM_MF_FAT Microtubule motor activity 6 0.020 DNALI1, KIF1B, KIF6, KIF17, CENPE, KIF16B 0.59 
GOTERM_MF_FAT Motor activity 8 0.026 DNALI1, KIF1B, DNAI1, MYH1, KIF6, KIF17, CENPE, KIF16B 0.62 
GOTERM_BP_FAT Microtubule-based movement 7 0.027 KIF1B, KIF6, KIF17, CENPE, KIF16B, DST, HAP1 1.00 
GOTERM_CC_FAT Microtubule cytoskeleton 19 0.031 
KIF17, CENPE, AKAP9, VPS41, WRN, AKAP11, KIF16B, 
KIAA1009, DNALI1, CDC45, KIF1B, DNAI1, KIF6, ANXA11, 
NINL, MAP4, MAP7, MAP9, DST    
0.55 
SP_PIR_KEYWORDS Microtubule 10 0.037 KIF1B, DNAI1, KIF6, KIF17, NINL, MAP4, CENPE, MAP7, KIF16B, MAP9 0.45 
GOTERM_CC_FAT Microtubule 11 0.053 KIF1B, DNAI1, KIF6, KIF17, NINL, MAP4, VPS41, CENPE, MAP7, KIF16B, MAP9 0.57 
GOTERM_CC_FAT Microtubule associated complex 6 0.056 DNALI1, KIF1B, DNAI1, KIF17, MAP4, MAP7 0.58 
GOTERM_BP_FAT Microtubule-based process 9 0.14 
KIF1B, KIF6, KIF17, CENPE, MAP7, KIF16B, TACC3, DST, 
HAP1 1.00 
Annotation cluster 7 Enrichment score: 1.59 
Category Term Count P Genes P-Benjamini 
INTERPRO Forkhead-associated 4 0.023 KIF1B, MKI67, KIF16B, FHAD1 0.86
UP_SEQ_FEATURE Domain: FHA 4 0.024 KIF1B, MKI67, KIF16B, FHAD1 0.84 
SMART FHA 4 0.030 KIF1B, MKI67, KIF16B, FHAD1 0.83 
Annotation cluster 8 Enrichment score: 1.42 
Category Term Count P Genes P-Benjamini 
GOTERM_CC_FAT Basolateral plasma membrane 11 8.5x10
-3 SLC4A11, NRAP, MYH1, ERBB2IP, CD44, LPP, P2RY2, NOTCH4, MAP7, KBTBD10, DST       0.38 
GOTERM_CC_FAT Cell junction 20 9.2x10-3 
PANX1, AMTN, MYH1, LPP, CDHR2, LMO7, GRIN3B, CDSN, 
CTNNA3, PPP1R9B, NRAP, CHRNA9, ERBB2IP, CD44, WNK4, 
SYNM, KBTBD10, DST, GRID1, CHRNG 
0.35 
GOTERM_CC_FAT Anchoring junction 9 0.024 NRAP, MYH1, CD44, LPP, LMO7, SYNM, KBTBD10, CDSN, CTNNA3 0.58 
GOTERM_CC_FAT Cell-substrate junction 7 0.026 NRAP, MYH1, ERBB2IP, CD44, LPP, KBTBD10, DST 0.57 
GOTERM_CC_FAT Adherens junction 8 0.04 NRAP, MYH1, CD44, LPP, LMO7, SYNM, KBTBD10, CTNNA3     0.57 
GOTERM_CC_FAT Cell-substrate adherens junction 5 0.17 NRAP, MYH1, CD44, LPP, KBTBD10   0.79 
GOTERM_CC_FAT Focal adhesion 4 0.34 MYH1, CD44, LPP, KBTBD10 0.92 
Annotation cluster 9 Enrichment score: 1.39 
Category Term Count P Genes P-Benjamini 
GOTERM_CC_FAT Basement membrane 7 5x10-3 AMTN, ERBB2IP, FBN1, DST, COL5A1, USH2A, MMRN2 0.37
GOTERM_CC_FAT Extracellular matrix part 8 9.7x10
-3 AMTN, ERBB2IP, FBN1, COL6A1, DST, COL5A1, USH2A, MMRN2 0.33 
GOTERM_CC_FAT Extracellular matrix 13  0.049 AMBN, AMTN, ERBB2IP, CD44, SPARCL1, FBN1, COL6A2, SFTPD, COL6A1, DST, COL5A1, USH2A, MMRN2 0.61 
GOTERM_CC_FAT Proteinaceous extracellular matrix 12 0.061 
AMBN, AMTN, ERBB2IP, SPARCL1, FBN1, COL6A2, SFTPD, 
COL6A1, DST, COL5A1, USH2A, MMRN2 0.57 
  
SP_PIR_KEYWORDS Extracellular matrix 9 0.098 AMBN, SPARCL1, FBN1, COL6A2, SFTPD, COL6A1, DST, COL5A1, MMRN2 0.67 
GOTERM_MF_FAT Integrin binding 3 0.34 ERBB2IP, DST, COL5A1    0.98 
Annotation cluster 10 Enrichment score: 1.31 
Category Term Count P Genes P-Benjamini 
SP_PIR_KEYWORDS Hydroxyproline 5 5.5x10-3 FCN2, COL6A2, SFTPD, COL6A1, COL5A1 0.23 
INTERPRO Collagen triple helix repeat 7 6.5x10
-3 C1QTNF6, FCN2, COL6A2, SFTPD, COL6A1, COL5A1, COL20A1 0.59 
SP_PIR_KEYWORDS Collagen 7 0.010 C1QTNF6, FCN2, COL6A2, SFTPD, COL6A1, COL5A1, COL20A1 0.28 
SP_PIR_KEYWORDS Hydroxylysine 4 0.022 COL6A2, SFTPD, COL6A1, COL5A1 0.39 
UP_SEQ_FEATURE Domain: collagen-like 4 0.033 C1QTNF6, FCN2, SFTPD, COL20A1 0.89 
SP_PIR_KEYWORDS Hydroxylation 5 0.049 FCN2, COL6A2, SFTPD, COL6A1, COL5A1 0.52 
KEGG_PATHWAY ECM-receptor interaction 5 0.059 CD44, COL6A2, COL6A1, ITGA3, COL5A1 1.00 
UP_SEQ_FEATURE Region of interest: triple-helical region 3 0.073 COL6A2, COL6A1, COL5A1   0.94 
SP_PIR_KEYWORDS Trimer 3 0.09 COL6A2, COL6A1, COL5A1 0.65 
SP_PIR_KEYWORDS Triple helix 3 0.12 COL6A2, COL6A1, COL5A1 0.7X 
SP_PIR_KEYWORDS Pyroglutamic acid 3 0.22 COL6A2, COL6A1, COL5A1 0.82 
SP_PIR_KEYWORDS Blocked amino end 4 0.26 COL6A2, SFTPD, COL6A1, ANXA13 0.83 
KEGG_PATHWAY Focal adhesion 6 0.28 COL6A2, COL6A1, ITGA3, EGF, COL5A1, MYLK 0.99 
Gene-set enrichment analysis of gene-based P-values from SKAT-O was performed using the functional annotation clustering analysis module of the bioinformatic tool DAVID. The DAVID tool 
provides a comprehensive set of functional annotation tools to understand biological meaning (i.e, to discover enriched functional-related gene groups, enriched biological themes) from large list of 
genes. Each annotation term group is assigned an enrichment score (ES) to rank overall importance. Only annotation clusters with ES≥1.3 (indicating biological significance) are shown. The 
significance of gene-term enrichment was assessed with a modified Fisher´s exact test and P-values are corrected using Benjamini-Hochberg’s by false discovery rate (FDR-BH) procedure. 
  
 
 
 
 
 
 
Supplementary Table 4. Clinical information recorded from anthracycline-treated 
pediatric cancer patients 
Clinical information 
Age at diagnosis (years)* 
Gender 
Primary tumor site 
Metastasis at diagnosis 
Metastasis during/after completion of treatment 
Relapse 
Family history of cardiovascular disease 
Anthracycline type 
Cumulative anthracycline dose (mg/m2)a* 
Radiotherapy involving the heartb 
Concomitant therapyc 
Pre-existing cardiac risk factorsd 
Hematopoietic progenitor cell transplantation 
Echocardiographic information 
Status (alive/dead) 
Last date of follow-up 
Information regarding patient demographic and clinical characteristics and therapy was abstracted 
from medical records. Clinical factors with associated P<0.05 in univariable analyses are indicated 
in bold type. * Covariates for single-variant, gene-based and pathway tests. a Cumulative 
anthracycline dose was calculated using doxorubicin equivalents according to the Children's 
Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and 
Young Adult Cancers [48]. b Radiotherapy involving the heart includes mediastinal and mantle 
radiation and total body irradiation. c Bleomycin concomitant administration was significantly 
associated in univariable analysis. d Pre-existing cardiac risk factors include hypertension, 
diabetes and obesity. 

